The present study showed that patients with HER2-positive expression before neoadjuvant therapy had a better prognosis, which was correlated with the better outcomes brought by the HER2-targeted therapy, and this is consistent with the results of some studies in HER2-positive breast cancer (26). Here, ERBB2 is linked to breast carcinoma.